{"filings":[{"id":816476,"accession_number":"0001628280-26-040051","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2026-06-03T13:02:51+00:00","items":["5.07"],"status":"ready","headline":"Crescent Biopharma shareholders re-elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jonathan Violin, Ph.D. elected Class II director with 2,890,000 votes (all from preferred shares).","Susan Moran, M.D., MSCE elected Class II director with 21,401,136 votes FOR; 136,056 WITHHELD.","Ratification of PricewaterhouseCoopers as auditor approved with 21,049,101 FOR (1,452 against).","Non-binding say-on-pay approved: 18,346,099 FOR; 300,217 AGAINST. Board set future vote every 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91791,"accession_number":"0001628280-26-028386","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crescent Biopharma Q1 net loss $23.3M; cash $189.2M funds ops into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.3M ($0.70/sh) vs $15.1M ($19.63/sh) in Q1 2025; revenue $1.0M from Kelun-Biotech license.","R&D expenses $17.9M (up 69% YoY) on CR-001/CR-002 development; G&A $7.9M (up 119% YoY).","Cash $189.2M as of March 31, 2026; expected to fund operations into 2028.","CR-001 ASCEND trial enrollment ongoing; proof-of-concept data expected Q1 2027.","CR-002 IND submission on track for mid-2026; clinic entry H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1039000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102132,"accession_number":"0001628280-26-011988","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crescent Biopharma reports FY2025 net loss $153.9M, revenue $10.8M; cash $213.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $92.4M ($4.01 per share) for Q4 2025 vs. $15.2M in prior year; FY net loss $153.9M.","Revenue of $10.8M in 2025 from $20M upfront from Kelun-Biotech license deal; no revenue in 2024.","R&D expenses surged to $138.1M in FY2025 (vs. $14.0M in 2024) driven by CR-003 license payment and pipeline costs.","Cash and equivalents $213.2M at Dec 31, 2025; expected to fund operations into 2028 after $185M private placement.","Strategic partnership with Kelun-Biotech for CR-001 (PD-1 x VEGF) and CR-003 (ITGB6 ADC); ASCEND Ph1/2 trial dosed first patient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10844000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118447,"accession_number":"0001628280-25-055221","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Crescent Biopharma partners with Kelun-Biotech on CR-001/SKB105, raises $185M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licenses CR-001 to Kelun-Biotech for Greater China; receives $20M upfront and up to $30M milestones.","In-licenses SKB105 (ADC) from Kelun for ex-China markets; pays $80M upfront and up to $1.25B milestones.","Private placement of ~$185M at $13.41/share, led by Jefferies and others; closing expected Dec 8, 2025.","Cash runway extended into 2028; Phase 1/2 monotherapy trials for CR-001 and SKB105 expected Q1 2026.","Pipeline milestones set through 2027; combination trials of CR-001 with ADCs planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118446,"accession_number":"0001628280-25-049865","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Crescent Bio Q3 net loss $24.6M; cash $133.3M; CR-001 IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.6M ($1.27 per share) for Q3 2025; R&D expense $20.3M, G&A $5.5M.","Cash position $133.3M as of Sept 30, 2025, expected to fund operations through 2027.","IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; Phase 1 start Q1 2026.","Preclinical data for CR-001 presented at SITC showing cooperative pharmacology and anti-tumor activity.","ADC program CR-002 IND submission expected mid-2026; CR-003 also advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134883,"accession_number":"0001628280-25-036846","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Crescent Biopharma Q2 net loss $21.8M; merger & $200M financing closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.8M ($4.93/share) for Q2 2025; R&D $12.1M, G&A $8.9M.","Cash $152.6M as of June 30, 2025, expected to fund operations through 2027.","Completed merger with GlycoMimetics and closed $200M private financing.","IND for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; proof-of-concept data H2 2026.","Adopted Executive Severance Plan with change-in-control benefits for executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151840,"accession_number":"0001104659-25-060714","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["1.01","2.01","5.02","9.01","2.02","3.03","4.01","5.01","5.03","5.05","5.06","7.01"],"status":"ready","headline":"Crescent Biopharma completes reverse merger with GlycoMimetics; post-merger shares trade under CBIO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Former GlycoMimetics securityholders own ~2.7% of combined company; Crescent holders own ~97.3% on fully diluted basis.","Crescent raised ~$200M gross proceeds via pre-closing financing: 85.5M shares and 19.1M pre-funded warrants.","Exchange ratio set at 0.1445 GlycoMimetics shares per Crescent share; 1-for-100 reverse stock split effected.","Combined company has ~19.5M shares outstanding (including warrants and convertible preferred) post-merger.","Company name changed to Crescent Biopharma, Inc.; stock trades under symbol CBIO on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151839,"accession_number":"0001104659-25-057078","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.","Board approved 1-for-100 reverse stock split; outstanding shares reduced from ~64.5M to ~0.6M.","Post-merger combined company to trade as Crescent Biopharma, Inc. (CBIO) on Nasdaq starting June 16, 2025.","Combined company expected to have ~14.8M shares outstanding (~25.3M fully diluted) post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151838,"accession_number":"0001104659-25-054587","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GlycoMimetics supplements merger disclosures; clarifies Crescent selection, $125M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["GlycoMimetics chose Crescent over Party A (Chinese parent) due to regulatory clearance timing risks.","Transaction terms: $8M enterprise value for GLYC, $50M for Crescent, $125M concurrent PIPE.","No GlycoMimetics executives will be retained or receive equity post-closing; no financial projections made.","Term Sheet Committee formed with Mr. Junius and Mr. Pearson; dissolved after Merger Agreement execution.","Supplemental tables update precedent IPOs, public companies, M&A, and reverse merger comparisons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151837,"accession_number":"0001104659-25-040386","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.","Each Crescent share to receive approximately 15.4192 shares of GlycoMimetics common stock.","Post-merger, GlycoMimetics holders expected to own ~2.6%; Crescent holders ~97.4% (fully diluted).","GlycoMimetics net cash at closing assumed at $1.8 million for ownership calculation.","Certificate of Designation for Series A Non-Voting Preferred Stock updated to clarify voting mechanics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170708,"accession_number":"0001558370-25-001517","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.02","5.02"],"status":"ready","headline":"GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.","CEO Harout Semerjian and CFO Brian Hahn ceased employment on Feb 21, 2025; severance payments of $1,365,456 and $480,991 respectively.","Five directors (Goldberg, Jackson, King, Koenig, Semerjian) resigned Feb 21, 2025; no disagreement with company operations.","Semerjian consulting: $700/hr for 12 months; Hahn consulting: $15,000/month through change in control or Sep 30, 2025.","Company is pursuing a merger with Crescent Biopharma (Form S-4 filed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170707,"accession_number":"0001558370-25-001016","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.","Exchange ratio ~14.9149 Crescent shares per GLYC share; based on Sep 30 caps.","A&R Purchase Agreement: $200M Crescent securities purchased pre-closing, replacing post-closing GLYC financing.","Amendment adjusts filings; S-4 registration statement and company stockholder approval sequence updated.","Condition: GLYC net cash at closing must be ~$1.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170706,"accession_number":"0001558370-25-000576","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO and CFO to depart GlycoMimetics by March 31; will consult through merger close","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Harout Semerjian and CFO Brian Hahn notified board of intent to resign by March 31, 2025.","Both expected to enter consulting agreements through expected close of merger with Crescent Biopharma.","Departures coincide with pending merger; no replacements named yet.","Notice date: January 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170705,"accession_number":"0001104659-25-002893","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GlycoMimetics files updated investor presentation for Crescent Biopharma merger","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Investor presentation for proposed merger with Crescent Biopharma updated as of January 2025.","Presentation furnished under Regulation FD and includes proxy solicitation materials for stockholder vote.","No new financial projections or merger consideration details disclosed in the filed exhibit.","Supplemental to prior proxy statement filed with the SEC on April 1, 2024.","Merger requires stockholder approval; no change to expected timeline communicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187679,"accession_number":"0001558370-24-016472","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GlycoMimetics gets Nasdaq extension to June 16, 2025; stock transferred to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension until June 16, 2025 to meet $1.00 minimum bid price for continued listing.","Common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective December 20, 2024.","If bid price closes at $1.00 or more for 10 consecutive business days before deadline, compliance is achieved.","Company may consider a reverse stock split to regain compliance; no assurance of success.","Failure to comply by June 16, 2025 may lead to delisting, subject to appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187678,"accession_number":"0001104659-24-115355","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GlycoMimetics and Crescent update merger investor presentation; no new deal terms disclosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GlycoMimetics furnished updated investor presentation (Exhibit 99.1) for proposed merger with Crescent Biopharma.","Presentation dated November 2024 contains no new financial terms, valuation, or timeline.","No changes to previously announced merger agreement structure or closing conditions were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187677,"accession_number":"0001104659-24-112054","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"GlycoMimetics merges with Crescent in reverse acquisition; uproleselan trial fails","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Crescent stockholders will own ~86.21% of combined company; GlycoMimetics stockholders ~13.79%.","Concurrent $200M PIPE financing from institutional investors; closing conditioned on merger.","NCI Phase 2/3 trial of uproleselan in AML failed to show statistically significant improvement in EFS or OS.","Merger expected to close in Q2 2025; combined company to be led by Crescent's CEO and board.","Support agreements cover ~98% of Crescent stock and ~9% of GlycoMimetics stock; 180-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204157,"accession_number":"0001558370-24-010370","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"GlycoMimetics cuts 80% workforce, begins strategic review after FDA setback for uproleselan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA feedback requires an additional clinical trial for uproleselan in R/R AML; regulatory path uncertain.","Workforce reduced by 26 employees (~80%); expects $3.6M in severance charges in Q3 2024.","CMO Dr. Edwin Rock departs July 31; will receive 12 months' base salary severance and consulting deal.","Cash and equivalents ~$31.3M as of March 31; restructuring extends cash runway into Q2 2025.","Engaged Lucid Capital Markets to explore strategic alternatives including sale, merger, or licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220892,"accession_number":"0001558370-24-009508","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GlycoMimetics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 21, 2024 for bid price below $1.00 for 30 consecutive business days.","Has until December 18, 2024 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.","Failure to regain compliance could result in delisting of GLYC common stock from Nasdaq.","Company intends to monitor bid price and consider options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220891,"accession_number":"0001558370-24-009140","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GlycoMimetics grants performance-based stock options to NEOs vesting on FDA approval of uproleselan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Harout Semerjian granted 521,250 shares; CFO Brian Hahn and CMO Edwin Rock each granted 187,500 shares.","Options have exercise price of $0.2589 per share and vest upon FDA approval of uproleselan for AML.","Awards are in addition to service-based options granted Jan 12, 2024 with exercise price of $3.11 per share.","Vesting is contingent on continued service through the FDA approval date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220890,"accession_number":"0001558370-24-008882","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GlycoMimetics Phase 3 uproleselan misses primary OS endpoint; positive subgroup in primary refractory AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 missed primary endpoint: mOS 13.0 vs 12.3 months (HR 0.89; 95% CI 0.69-1.15), not statistically significant.","In primary refractory AML (n=128), mOS improved to 31.2 vs 10.1 months (HR 0.58; 95% CI 0.37-0.91).","Safety consistent with chemotherapy; no new adverse event signals.","Company planning to engage regulators and NCI; Phase 2/3 study in frontline AML advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220889,"accession_number":"0001558370-24-006793","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GlycoMimetics' pivotal Phase 3 trial of uproleselan in R/R AML fails to meet primary endpoint of overall survival","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 study (388 patients) of uproleselan + chemo did not achieve statistically significant improvement in overall survival vs chemo alone.","Median overall survival 13 months (uproleselan) vs 12.3 months (placebo).","NCI Phase 2/3 study in newly diagnosed AML remains ongoing; company will submit data to medical meeting.","Cash and cash equivalents $31.3M as of March 31, 2024, down from $41.8M at Dec 31, 2023.","Q1 2024 R&D expenses $6.0M, G&A $5.1M; shares outstanding 64.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220888,"accession_number":"0001558370-24-006459","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"GlycoMimetics stockholders approve increase in authorized shares to 150M and officer exculpation amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted to increase authorized common stock from 100M to 150M shares (49.3M for, 1.0M against).","Amendment adding Delaware-law officer exculpation provision approved (36.2M for, 1.0M against, 13.2M broker non-votes).","Directors Daniel Junius and Rachel King elected with 34.6M and 37.0M votes for, respectively.","Ratification of Ernst & Young as independent auditor for FY2024 passed with 50.3M votes for.","Advisory vote on executive compensation approved with 35.3M for, 1.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240481,"accession_number":"0001558370-24-004015","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics reports Q4/FY2023 cash $41.8M; Phase 3 uproleselan topline in Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $41.8M at Dec 31, 2023, down from $47.9M at Dec 31, 2022.","Phase 3 uproleselan topline results expected Q2 2024; NDA submission by end-2024 if positive.","Phase 1a GMI-1687 met primary and secondary endpoints; research agreement with ASH RC for SCD.","R&D expenses FY2023 $20.1M (down from $28.4M); G&A $19.2M (flat vs $19.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240480,"accession_number":"0001558370-24-002241","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GlycoMimetics files 8-K with corporate presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes a slide presentation for anticipated investor meetings, March 2024.","Presentation focuses on GlycoMimetics' glycobiology-based therapeutic platform.","No specific financial results, pipeline updates, or guidance changes provided in the filing.","The presentation contains forward-looking statements and standard disclaimers.","No new agreements, regulatory decisions, or material events were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240479,"accession_number":"0001558370-24-000013","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"GlycoMimetics signs commercial manufacturing deal with Thermo Fisher's Patheon for uproleselan","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Agreement covers commercial supply of injectable uproleselan if FDA approves the drug.","Initial term through Dec 31, 2026, auto-renews for 3-year periods unless terminated.","Company provides API; Patheon supplies other raw materials, packaging, and QC testing.","Company gave Patheon a forecast of required annual volumes through 2027.","Either party may terminate after initial term with 18 months' notice; termination fees apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257995,"accession_number":"0001558370-23-017507","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics Q3 cash $49.4M; uproleselan Phase 3 topline by Q2 2024; NDA filing by end 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $49.4M as of Sep 30, 2023; no revenue reported (pre-revenue biotech).","Pivotal Phase 3 uproleselan topline results on track for end of Q2 2024; NDA filing expected by end 2024.","Phase 1a GMI-1687 initial results expected by end of Q1 2024 as potential sickle cell disease treatment.","R&D expenses $5.3M (up from $4.9M) driven by GMI-1687 trial; G&A expenses $4.5M (up from $3.8M).","Updated uproleselan data in secondary AML to be presented at ASH December 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275308,"accession_number":"0001558370-23-012816","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics Q2 cash $58M; uproleselan Phase 3 topline by Q2 2024; GMI-1687 Phase 1a in Q3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $58.0M at June 30, 2023, up from $47.9M at Dec 31, 2022; R&D spend $4.1M, down 49% YoY.","Pivotal Phase 3 uproleselan R/R AML topline results expected by end of Q2 2024 after time-based analysis amendment.","FDA agreed to initial Pediatric Study Plan; NCI will sponsor Phase 1/2 uproleselan study in pediatric AML.","First pediatric patient dosed in investigator-initiated Phase 1/2 study of uproleselan with pre-transplant conditioning.","GMI-1687 (E-selectin antagonist) Phase 1a study in healthy volunteers to initiate in Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292776,"accession_number":"0001558370-23-010301","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GlycoMimetics stockholders elect all director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three director nominees elected: Andrews (36.2M for, 0.5M withheld), Goldberg (32.6M/4.0M), Pearson (36.3M/0.4M); 14.2M broker non-votes.","Ratification of Ernst & Young as auditor approved: 50.3M for, 0.5M against, 0.05M abstained.","Advisory vote on executive compensation approved: 36.1M for, 0.4M against, 0.1M abstained; 14.2M broker non-votes.","Approximately 79% of outstanding shares (50.9M of 64.2M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292775,"accession_number":"0001558370-23-007746","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics Q1 cash $65M; uproleselan Phase 3 trial on track for H1 2024 survival trigger","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $65.0M as of March 31, 2023, up from $47.9M at Dec 31, 2022; raised $28.7M via ATM.","R&D expenses fell to $5.4M from $9.6M YoY on lower clinical trial costs after Phase 3 enrollment completed.","Phase 3 uproleselan study continues; final overall survival event trigger projected within first half of 2024.","Cash runway expected to fund operations into late Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292774,"accession_number":"0001558370-23-006434","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GlycoMimetics amends lease: reduces footprint by ~12,000 sq ft, extends remaining to Jan 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for ~42,000 sq ft in Rockville, MD amended; ~12,000 sq ft terminates Oct 31, 2023; remaining ~30,000 sq ft extended to Jan 31, 2025.","Annual base rent on extended portion increases 3% on Nov 1, 2023 and Nov 1, 2024.","No further right to extend lease term beyond Jan 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313434,"accession_number":"0001558370-23-004866","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics reports $47.9M cash; Phase 3 uproleselan trial continues to final events in H1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $47.9M at Dec 31, 2022; raised $28.7M net from ATM in Q1 2023.","R&D expenses fell to $5.9M in Q4 2022 from $12.9M in Q4 2021; full-year R&D $28.4M vs $47.5M.","DMC recommended Phase 3 uproleselan trial continue after interim utility analysis; final OS events expected H1 2024.","Appointed Edwin Rock as CMO, Bruce Johnson as CCO, and Chinmaya Rath as CBO in 2022-2023.","Cash runway projected to fund operations to end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313433,"accession_number":"0001558370-23-003498","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"GlycoMimetics discloses $2M deposit at Silicon Valley Bank; says amount immaterial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds approximately $2M in cash deposits at Silicon Valley Bank.","GlycoMimetics considers the deposit amount immaterial to its overall liquidity.","Disclosure filed March 10, 2023, amid SVB's collapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313432,"accession_number":"0001558370-23-002692","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GlycoMimetics files 8-K with corporate presentation for investor meetings; no specific material facts disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes a slide presentation dated March 2, 2023, for anticipated investor meetings.","No financial results, clinical data, or other material updates are provided in the filing text.","The exhibit content was not included in the provided text, so specific details are unavailable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313431,"accession_number":"0001558370-23-001631","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GlycoMimetics CSO John Magnani to depart March 31; consulting through June 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. John Magnani, SVP Research and CSO, employment ends March 31, 2023.","Severance of $40,000 payable in equal installments over 3 months after separation.","Company will pay COBRA premiums for 15 months post-separation.","Consulting agreement from April 1, 2023 through June 30, 2024 for continued equity vesting.","Consulting services provided at request of CEO or designee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331941,"accession_number":"0001558370-22-017028","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics reports Q3 2022 financials; FDA clears interim analysis for uproleselan Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $51.6M as of Sep 30, 2022 vs $90.3M at Dec 31, 2021; cash runway extended to end of 2023.","FDA cleared protocol amendment for interim utility analysis of uproleselan Phase 3 in relapsed/refractory AML.","Blinded pooled survival data show patients living longer than historically expected; DMC meeting by end Q1 2023.","Final survival events trigger projected around year-end 2023, later than originally anticipated.","R&D expenses decreased to $4.9M from $13.3M YoY due to Phase 3 enrollment completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331940,"accession_number":"0001558370-22-014828","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GlycoMimetics files 8-K with slide presentation for investor meetings; content not disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide presentation furnished as Exhibit 99.1 for investor meetings on October 4, 2022.","No financial or clinical data from the presentation is included in this filing.","The presentation is provided under Regulation FD and is not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349396,"accession_number":"0001558370-22-011768","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics Q2 cash $60.2M; FDA clears GMI-1687 IND; uproleselan Phase 3 data expected mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $60.2M as of June 30, 2022, down from $90.3M at Dec 31, 2021.","R&D expenses $8.0M (down from $10.2M YoY) due to lower uproleselan trial costs after enrollment ended.","G&A expenses $5.5M (up from $4.2M) for commercial start-up costs for uproleselan.","FDA cleared IND for GMI-1687 in sickle cell disease; company seeks licensing partner.","Phase 3 uproleselan trial (n=388) on track; survival events trigger expected mid-2023 with top-line data soon after."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":75000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366329,"accession_number":"0001558370-22-009711","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GlycoMimetics receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bid price below $1.00 for 30 consecutive business days; 180-day cure period until Nov 28, 2022.","Compliance requires closing bid price at or above $1.00 for at least 10 consecutive business days.","If not cured, Company may transfer to Nasdaq Capital Market for additional 180-day period if eligible.","Noncompliance has no immediate effect on listing or trading of common stock on The Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366328,"accession_number":"0001104659-22-063262","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"GlycoMimetics stockholders approve 2.6M share increase to equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2013 Equity Incentive Plan, increasing share reserve by 2,619,622 shares.","All three director nominees (Scott Jackson, Scott Koenig, Harout Semerjian) were elected.","Ratification of Ernst & Young as independent auditor passed with 38,971,830 votes for.","Advisory vote on executive compensation approved with 27,132,991 votes for.","Annual meeting had 75% of shares present or represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366327,"accession_number":"0001558370-22-006206","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics Q1 cash $76.5M; Phase 3 uproleselan OS events trigger now mid-2023; workforce cut 20%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents $76.5M at March 31, 2022, down from $90.3M at Dec 31, 2021.","Phase 3 uproleselan trial in relapsed/refractory AML expects OS events trigger mid-2023, top line data shortly after.","IND-enabling studies for GMI-1687 completed; submission on track for H1 2022 in sickle cell disease VOC.","Workforce reduced by 20% in April, mainly early-stage research; executive team added CCO and VP of Tech Ops.","R&D expenses $9.6M (down from $11.1M); G&A $5.1M (up from $4.2M); no revenue recognized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385815,"accession_number":"0001558370-22-002741","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics reports cash $90.3M; Phase 3 uproleselan data still after 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $90.3M at Dec 31, 2021 vs $137.0M at Dec 31, 2020; revenue fell to $1.2M from $10.2M.","Pivotal Phase 3 uproleselan trial in relapsed/refractory AML completed enrollment (388 patients); top-line data expected after year-end 2022.","NCI Phase 2/3 registration trial (newly diagnosed AML) completed Phase 2 enrollment (267 patients); interim analysis planned.","Apollomics initiated Phase 3 uproleselan trial in Greater China in November 2021 after Breakthrough Therapy designation.","Expanded executive team: hired Lisa DeLuca (VP Regulatory), Bruce Johnson (SVP/Chief Commercial Officer), Deepak Tiwari (VP Technical Operations)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385814,"accession_number":"0001558370-22-000516","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"GlycoMimetics awards retention bonuses to CFO, CBO, CSO; induces plan shares to 3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Brian Hahn and CBO Armand Girard eligible for retention bonus up to 60% of base salary; CSO John Magnani up to 20%.","40% of bonus payable Aug 1, 2022; remaining 60% payable Aug 1, 2023, contingent on continued employment through each date.","Inducement Plan share reserve increased from 2M to 3M shares to support equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403707,"accession_number":"0001558370-21-014000","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GlycoMimetics Q3 cash $101.9M; uproleselan Phase 3 enrollment nearing completion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $101.9M at Sept 30, 2021, down from $137.0M at Dec 31, 2020.","R&D expenses increased to $13.3M from $10.7M YoY, driven by Phase 3 trial costs.","Phase 3 trial of uproleselan in relapsed/refractory AML nearing enrollment completion; top line data after 2022.","Data published in BLOOD showed 69% MRD negative rate in evaluable relapsed/refractory AML patients.","New CEO Harout Semerjian appointed effective August 6, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1142142.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422661,"accession_number":"0001558370-21-010404","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"GlycoMimetics names Harout Semerjian CEO to succeed retiring Rachel King; Q2 cash $118.9M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Rachel King retires effective Aug 6, 2021; remains on board and as consultant. Harout Semerjian appointed CEO effective Aug 6.","New CEO receives $595K salary, $200K sign-on bonus, target bonus 55%, and stock options for ~1.65M shares with milestone-based vesting.","As of June 30, 2021, cash and equivalents $118.9M (down from $137.0M at Dec 31, 2020); Q2 R&D $10.2M, G&A $4.2M.","Enrollment in Phase 3 relapsed/refractory AML trial and NCI Phase 2/3 trial expected to complete by year-end 2021.","Compensation Committee increased Inducement Plan shares from 500K to 2M; grants to new CEO from this plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":591004466.2647908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}